Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice.
immune checkpoints inhibitor
new biomarkers
renal cancer carcinoma
targeted therapy
tyrosine kinase inhibitor (TKI)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
01
2021
accepted:
29
03
2021
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
epublish
Résumé
The therapeutic sc"enario of metastatic renal cell cancer (mRCC) has noticeably increased, ranging from the most studied molecular target therapies to those most recently introduced, up to immune checkpoint inhibitors (ICIs). The most recent clinical trials with an ICI-based combination of molecular targeted agents and ICI show how, by restoring an efficient immune response against cancer cells and by establishing an immunological memory, it is possible to obtain not only a better radiological response but also a longer progression-free and overall survival. However, the role of tyrosine kinase inhibitors (TKIs) remains of fundamental importance, especially in patients who, for clinical characteristics, tumor burden and comorbidity, could have greater benefit from the use of TKIs in monotherapy rather than in combination with other therapies. However, to use these novel options in the best possible way, knowledge is required not only of the data from the large clinical trials but also of the biological mechanisms, molecular pathways, immunological mechanisms, and methodological issues related to both new response criteria and endpoints. In this complex scenario, we review the latest results of the latest clinical trials and provide guidance for overcoming the barriers to decision-making to offer a practical approach to the management of mRCC in daily clinical practice. Moreover, based on recent literature, we discuss the most innovative combination strategies that would allow us to achieve the best clinical therapeutic results.
Identifiants
pubmed: 33968762
doi: 10.3389/fonc.2021.657639
pmc: PMC8100507
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
657639Informations de copyright
Copyright © 2021 Roberto, Botticelli, Panebianco, Aschelter, Gelibter, Ciccarese, Minelli, Nuti, Santini, Laghi, Tomao and Marchetti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Sci. 2019 May;110(5):1564-1572
pubmed: 30861269
Ann Transl Med. 2019 Nov;7(22):648
pubmed: 31930049
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Clin Cancer Res. 2015 Mar 1;21(5):1071-7
pubmed: 25538263
Int J Mol Sci. 2019 Apr 04;20(7):
pubmed: 30987368
Clin Cancer Res. 2019 Oct 15;25(20):6080-6088
pubmed: 31371341
Nature. 2009 Nov 5;462(7269):104-7
pubmed: 19847165
J Geriatr Oncol. 2019 Jan;10(1):149-154
pubmed: 29861146
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Eur Urol. 2017 Oct;72(4):557-564
pubmed: 28413127
Clin Cancer Res. 2017 Aug 1;23(15):4270-4279
pubmed: 28223273
Anticancer Res. 2012 Dec;32(12):5447-51
pubmed: 23225450
Cancer Biol Ther. 2010 Jan;9(1):15-9
pubmed: 20009542
Oncotarget. 2017 May 16;8(20):33614-33620
pubmed: 28431395
Science. 2018 Jul 20;361(6399):290-295
pubmed: 30026228
N Engl J Med. 2018 Aug 02;379(5):417-427
pubmed: 29860937
J Immunother Cancer. 2018 Oct 22;6(1):109
pubmed: 30348216
Nature. 2013 Sep 19;501(7467):338-45
pubmed: 24048066
Eur Urol. 2021 May;79(5):659-662
pubmed: 32654802
J Clin Med. 2019 May 24;8(5):
pubmed: 31137694
Nat Cell Biol. 2020 Apr;22(4):465-475
pubmed: 32203421
J Clin Oncol. 2017 Feb 20;35(6):591-597
pubmed: 28199818
Ann Oncol. 2012 Jan;23(1):46-52
pubmed: 21464158
Cancer Immunol Res. 2016 Oct;4(10):820-822
pubmed: 27538576
Clin Cancer Res. 2015 Jul 1;21(13):3031-40
pubmed: 25688160
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Cancer Manag Res. 2018 Sep 11;10:3419-3431
pubmed: 30237743
Lancet Oncol. 2019 Feb;20(2):297-310
pubmed: 30658932
Ann Oncol. 2021 Mar;32(3):422-423
pubmed: 33271289
Ann Oncol. 2020 Aug;31(8):1030-1039
pubmed: 32339648
Lancet Oncol. 2020 Jan;21(1):95-104
pubmed: 31810797
Cell. 2018 Apr 19;173(3):595-610.e11
pubmed: 29656894
Clin Genitourin Cancer. 2019 Dec;17(6):e1147-e1152
pubmed: 31473121
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Cancer Discov. 2019 Apr;9(4):510-525
pubmed: 30622105
Cell Rep. 2018 Jun 19;23(12):3698
pubmed: 29925010
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
Eur Urol. 2018 Sep;74(3):309-321
pubmed: 29656851
Lancet Oncol. 2012 Aug;13(8):827-37
pubmed: 22759480
Nat Rev Cancer. 2008 Nov;8(11):865-73
pubmed: 18923434
Cancer Immunol Res. 2015 Dec;3(12):1303-7
pubmed: 26307625
Urol Oncol. 2018 Nov;36(11):499.e9-499.e16
pubmed: 30131293
Dis Markers. 2013;34(2):105-11
pubmed: 23324577
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Nat Genet. 2013 Aug;45(8):860-7
pubmed: 23797736
Br J Cancer. 2015 Aug 11;113(4):626-33
pubmed: 26135896
J Clin Oncol. 2005 Feb 1;23(4):832-41
pubmed: 15681528
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32221016
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s
pubmed: 17255298
Oncologist. 2015 Nov;20(11):1253-60
pubmed: 26424759
Cancer Immunol Res. 2015 Oct;3(10):1158-64
pubmed: 26014095
Cancer Immunol Res. 2015 Sep;3(9):1017-29
pubmed: 26014097
Target Oncol. 2016 Apr;11(2):143-8
pubmed: 26429561
ESMO Open. 2021 Feb;6(1):100025
pubmed: 33399087
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Cancer Cell. 2012 Jun 12;21(6):836-47
pubmed: 22698407
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Eur J Cancer. 2020 Feb;126:1-10
pubmed: 31887537
Genes Dev. 2007 Jul 15;21(14):1714-9
pubmed: 17639077
Lancet Oncol. 2020 Dec;21(12):1538-1539
pubmed: 33284112
Br J Cancer. 2018 Sep;119(6):663-669
pubmed: 30197417
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
BMC Cancer. 2020 Mar 12;20(1):207
pubmed: 32164651
J Cancer. 2014 Jan 24;5(3):166-72
pubmed: 24563671
Trends Cancer. 2018 Jul;4(7):472-484
pubmed: 29937046
J Transl Med. 2007 Jul 02;5:32
pubmed: 17605814
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
Radiology. 2014 Feb;270(2):464-71
pubmed: 24029645
Br J Cancer. 2016 Mar 15;114(6):642-9
pubmed: 26908330
Immunity. 2018 Mar 20;48(3):399-416
pubmed: 29562192
Cancer Res. 2001 Jul 1;61(13):5132-6
pubmed: 11431351
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Lancet Oncol. 2013 Feb;14(2):141-8
pubmed: 23312463
Cancer Cell. 2013 Jan 14;23(1):93-106
pubmed: 23273920
Ann Oncol. 2021 Jan;32(1):97-102
pubmed: 33010459
Br J Radiol. 2020 Apr;93(1108):20190948
pubmed: 32101448
Am J Clin Oncol. 2021 Mar 1;44(3):121-125
pubmed: 33617179
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Target Oncol. 2020 Aug;15(4):495-501
pubmed: 32671807
Eur Urol. 2020 Apr;77(4):449-453
pubmed: 31732098
PLoS One. 2018 Jul 6;13(7):e0199642
pubmed: 29979712
Genome Biol. 2016 Nov 17;17(1):231
pubmed: 27855702
Mod Pathol. 2015 Jun;28(6):845-853
pubmed: 25676555
AJR Am J Roentgenol. 2010 Jan;194(1):157-65
pubmed: 20028918
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Cancer Immunol Res. 2016 Sep 2;4(9):726-33
pubmed: 27491898
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Front Oncol. 2015 Sep 22;5:202
pubmed: 26442214
Eur Urol. 2018 Feb;73(2):308-310
pubmed: 28844598
J Immunother Cancer. 2018 Jan 25;6(1):4
pubmed: 29368638
Abdom Imaging. 2015 Aug;40(6):1684-92
pubmed: 25753955
Clin Genitourin Cancer. 2017 Aug;15(4):e573-e582
pubmed: 28139444
Urol Oncol. 2017 Aug;35(8):507-515
pubmed: 28551412
Nat Commun. 2016 Aug 30;7:12624
pubmed: 27571927
Nat Genet. 2013 Aug;45(8):849-50
pubmed: 23892664